Compare Neurocrine Biosciences Inc (NBIX) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs BlackRock TCP Capital Corp — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while BlackRock TCP Capital Corp trades at $3.24 (market cap $270.17M). The key difference: Neurocrine Biosciences Inc is far larger — about 64.4× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 26.09% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TCPC | |
|---|---|---|
Market Cap | $17.40B | $270.17M |
Sector | Health | Financials |
52-Week High | $180.55 | $7.64 |
52-Week Low | $123.10 | $3.14 |
Enterprise Value | $16.49B | — |
Dividend Yield | — | 26.09% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
